newsletter masthead
June 26, 2018
MEMBER/CENTER HIGHLIGHTS
VELOSANO BIKE TO CURE
Join Team Case CCC!
VeloSano logo
Register today for  VeloSano Bike to Cure , 20-22, 2018!  

It's hard to believe there is less than 1 month before VeloSano weekend!  Team Case CCC is going strong so far, and continuing to recruit at Case CCC institutions. 

Remember - to be eligible for Case CCC VeloSano pilot funding you must participate in VeloSano as a rider or volunteer and be a Case CCC member. 

We are one of the top teams - join us and help to raise money to fund cancer research in Cleveland! 
Basket Raffle! 
Team Case CCC is holding a fundraising basket raffle this week! All money raised goes to VeloSano Bike to Cure.  Tickets are $1 each or 6 for $5 (cash only). 

Ticket sales: 
  • Tues, Jun 26, 10a-2p - WRB Lobby
  • Wed, Jun 27, 10a-2p - WRB Lobby
  • Thurs, Jun 28, 10a-2p - BRB Lobby
  • Fri, Jun 29, 10a-12p - BRB Lobby
Winners will be drawn Fri, Jun 29 at 12p. 

Contact Team Captain Mary Wright at maw143@case.edu with any questions or to purchase tickets. 
MARK YOUR CALENDARS
Annual Scientific Retreat 2018
Jul 26-27, 2018
The Retreat Organizing Committee is excited to announce that  registration is open for the Case CCC scientific retreat, Jul 26-27, 2018.

The keynote address will be Hsing-Jien Kung delivered Thurs, Jul 26 at the Tinkham Veale University Center by Dr. Hsing-Jien Kung, Deputy Director and and Director of Basic Research and Distinguished Professor, Dept. Biochemistry and Molecular Medicine, UC Davis at University of California, Davis.  Thursday's program will also feature an update from Cancer Center Director Dr. Stan Gersona judged student/trainee poster session, and a reception. 

Friday's program will be held at Corporate College East. The agenda will focus on the scientific initiatives and really get into the research being conducted by our Center. Leaders of the scientific initiatives will provide a brief overview, then we will hear scientific presentations being conducted within those initiatives, plus presentations to highlight exciting services and technology provided by Cancer Center shared resources.  

CALL FOR ABSTRACTS
All students, postdocs, and fellows conducting cancer research are invited to submit abstracts. Cancer Center leadership will review abstracts based on the relationship to cancer, novelty, significance of findings, and clarity.  Monetary Prizes will be awarded.

Winners will be announced at the beginning of the general poster/networking session on Thurs, Jul 26. Winners will also have the opportunity to provide a one-minute "elevator pitch" highlighting their research at the general session of the retreat on Fri, Jul 27 in the presence of the Cancer Center membership. Winning posters will also be on display that day during the retreat wrap-up from 4:50-6:30p.

Abstract submission deadline is Fri, Jul 6 at 5p via email to   damian.junk@case.edu. Visit the retreat website for detailed instructions.

CSC 2018 - web banner

Cancer Stem Cell Conference
Aug 6-8, 2018 | Tinkham Veale 

The Case Comprehensive Cancer Center (Case CCC) and National Center for Regenerative Medicine (NCRM) invite you to Cancer Stem Cell Conference (CSC 2018)! Now in it's third year, CSC 2018 will feature renowned thought leaders in the field of cancer stem cell research. This conference is guaranteed to offer cutting-edge keynote presentations from a variety of niches within the field. Join world-class investigators for this 3-day summit and network with scientists and clinicians advancing cancer stem cell research and therapeutic applications.

Conference Highlights
  • The agenda will integrate invited talks from thought leaders in the CSC field with short talks from early-stage investigators and trainees selected from submitted abstracts.
  • Pre-conference career development workshop for junior faculty and trainees
    • Meet the Editors: Natalie Cain, PhD (CellReports), Mark Landis, PhD (CancerDiscovery) and Teodoro Pulvirenti, PhD (JEM)
    • Discussion of NIH grants: Michael Espey, PhD (NCI) and Michelle McGuirl, PhD (NIH)
  • Young Investigator Awards available to support travel for senior trainees or junior faculty (less than 5 years from their first independent position). 
  • Opportunity to share ideas with world-class investigators in stem cell research. 2016 CSC was attended by over 300 from 20 countries and 25 U.S. states. This year's conference is on track to attract a similar crowd of colleagues.
Keynote Speakers
Ned Sharpless
Norman 'Ned' E. Sharpless, MD
National Cancer Institute

John Condeelis
John S. Condeelis, PhD
Albert Einstein College of Medicine
Irving Weissman
Irving Weissman, PhD
Stanford University
Zena Werb
Zena Werb, PhD
University of California, San Francisco
 
IN THE NEWS
Crain's Cleveland Business - Jun 24, 2018
While some proton therapy centers across the country have reportedly struggled to stay profitable, officials at University Hospitals say they've found the "sweet spot" two years after the Cleveland-based health system opened its own $30 million center.  UH's Proton Therapy Center, which saw its first patient in July 2016 and is the only of its kind in the region, serves at least 20 patients a day, which puts the center in a financially healthy position to sustain its $25 million annual budget, said Dr. Ted Teknos, president and scientific director of UH Seidman Cancer Center and deputy director for University Hospitals, Case Comprehensive Cancer Center...Cleveland's other large health system, the Cleveland Clinic, has no plans to obtain proton therapy technology, said Dr. John Suh, chairman of the Department of Radiation Oncology at the Clinic's Taussig Cancer Center,  Case Comprehensive Cancer Center.
Medscape - Jun 22, 2018
Commentary from Dr.  Jack West, medical director of the thoracic oncology program at Swedish Cancer Institute in Seattle. Dr. Sumanta Kumar Pal, co-director of the kidney cancer program at City of Hope; and Dr. Timothy Gilligan, vice chair for education and associate professor at the Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center. 
Cancer Network - Jun 22, 2018
A large genomic analysis of more than 140,000 men identified more than 60 new prostate cancer susceptibility loci, including one locus significantly associated with early onset of the malignancy. The study could improve risk prediction and help elucidate the underlying biology of prostate cancer. " Although prostate cancer is the most common noncutaneous cancer among men in the Western world, and one in seven men will be diagnosed during their lifetime, very few modifiable risk factors have been established,"wrote study authors led by Fredrick R. Schumacher, PhD, MPH, of the Case Comprehensive Cancer Center, Case Western Reserve University in Cleveland. Previous genome-wide association studies have identified more than 100 gene variants associated with prostate cancer.  For the new studies, the researchers developed a custom high-density genotyping array (OncoArray). First, they applied this to a dataset from previously published studies of 46,939 prostate cancer cases and 27,910 controls with no known prostate cancer diagnosis. They then compared this with previously genotyped data from 32,255 prostate cancer cases and 33,202 controls, for a total of 79,194 cases and 61,112 controls. Results were  published  in Nature Genetics.
FUNDING OPPORTUNITIES
*NEW* Opportunities for Pilot Projects from Cancer Innovation Award
Deadline:  Aug 3, 2018
The Case Comprehensive Cancer Center is providing seed funding for highly innovative and impactful proposals that will generate key data for larger, nationally competitive grants. Projects must be transformative in nature and may focus on technology development, innovative biological or therapeutic questions, novel concepts in catchment-based research, or topics that have the potential to overturn dogma. Investigators should submit novel ideas which may be high risk but are exceptionally innovative.  This RFA is open to all Case Comprehensive Cancer Center Members. These projects must not be currently funded by other sources or by the Cancer Center.

AWARD DESCRIPTION
  • Up to 5 research projects will be funded. Total funds committed to this RFA are $250,000.
  • Each research project can request a budget of up to $50,000 for one year.
  • Research projects should be completed within one year.
*NEW*  Opportunities for Pilot Projects to Support New Collaborative Initiatives
Deadline:  Aug 17, 2018
The Case Comprehensive Cancer Center is providing seed funding for new collaborative multi-investigator and impactful proposals that will complement the Case CCC Scientific Initiatives and generate key data for larger, nationally competitive grants. Projects must be transformative in nature and focus on Genomics, Drug Discovery, Community and Disparities Research, AYA, Immunotherapy, Women's Cancers, or Brain Tumors. Investigators should submit ideas that will build new collaborations.  This RFA is open to all Case Comprehensive Cancer Center Members. These projects must not be currently funded by other sources or by the Cancer Center.

AWARD DESCRIPTION
  • Up to 5 research projects will be funded. Total funds committed to this RFA are $300,000.
  • Each research project can request a budget of up to $75,000 for one year.
  • Research projects should be completed within one year.
  • Research must include at least 1 project and 2 PIs.
Opportunities for Pilot Projects in Cancer Disparities Research
Deadline: Jul 2, 2018
The Office of Cancer Disparities Research of the Case Comprehensive Cancer Center is providing seed funding for highly innovative and impactful disparities-focused proposals that will generate key data for larger, nationally competitive grants. Attention to cancer disparities (or catchment area) is a cross-cutting theme across the scientific programs; thus projects aligned with the Center's strategic plan, and specifically the Community and Cancer Health Disparities scientific initiative, are preferred. Collaborative, multi-investigator projects are particularly encouraged. The main goal of this RFA is to stimulate novel research designed to (1) improve understanding of factors that contribute to cancer disparities and (2) develop and test interventions for reducing and ultimately eliminating them. Transdisciplinary, interprogrammatic, and translational approaches are especially encouraged, as are new investigator proposals.
NIH BULLETIN- Notices and Funding Opportunities
rfas 
Notices
Notice of Availability of Administrative Supplements for NIH Grants that are NOT Focused on Down Syndrome to Address Specific Down Syndrome Research Objectives (NOT-OD-18-194)

Notice of Availability of Administrative Supplements for NIH Grants Focused on Down Syndrome to Address Specific Down Syndrome Research Objectives (NOT-OD-18-195)

Program Announcements

Cooperative Human Tissue Network (CHTN) (UM1 Clinical Trial Not Allowed)(RFA-CA-18-025)
Deadline: Aug 28, 2018

Administrative Supplements to Promote Diversity in Research and Development  Small Businesses-SBIR/STTR (Admin Supp Clinical Trial Not Allowed)(PA-18-837)
Deadline: Rolling
IN THIS ISSUE
EVENTSevents
Tues, Jun 26
Cancer Impact Lecture
Patrick Gunning, PhD
Department of Chemistry and Physical Sciences, University of Toronto, Mississauga
"Drug discovery in academia"
1p NE1-205
Wed, Jun 27
Celebration of Analisa DiFeo and Goutham Narla
4:30p WRB Atrium
Thurs, Jun 28
Developmental Therapeutics Journal Club
9a R4-013
Fri, Jun 29
Taussig Cancer Institute Grand Rounds
8a CA5-120
Mon, Jul 2
Tumor Immunology and Immunotherapy Meeting
4p WRB 3-136
Tues, Jul 3
Cancer Center Research in Progress Seminar
3p WRB 3-136
Thurs, Jul 5
Developmental Therapeutics Journal Club
9a R4-013
Fri, Jul 6
Taussig Cancer Institute Grand Rounds
8a CA5-120

ADDITIONAL UPCOMING SYMPOSIUMS & EVENTS
prev-funding
PREVIOUSLY ANNOUNCED OPPORTUNITIES

Deadline: Open

Deadline: Open

Deadline: Open
Case Comprehensive Cancer Center 
2103 Cornell Road, Ste 1422
Cleveland, OH 44106-7285